SDZ 283471
Latest Information Update: 21 Jul 1998
Price :
$50 *
At a glance
- Originator Novartis
- Class Antivirals
- Mechanism of Action HIV protease inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported HIV infections
Most Recent Events
- 21 Jul 1998 No-Development-Reported for HIV infections treatment in Switzerland (Unknown route)
- 20 Jan 1995 Preclinical development for HIV infections treatment in Switzerland (Unknown route)